Fulcrum Therapeutics presented Phase 2 data at ASH 2023 showing pociredir increased fetal hemoglobin by 8.2% in sickle cell patients,…
sickle cell disease
1 post
Fulcrum Therapeutics presented Phase 2 data at ASH 2023 showing pociredir increased fetal hemoglobin by 8.2% in sickle cell patients,…